arrow
Y

Yuji Shimura

kyoto prefectural university of medicine
H指数:17
被引数:1,231

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome

非感染性发热定义高危骨髓增生异常综合征中预后较差的患者亚群

2026-05-100
PRE
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: A nationwide registry

复发或难治性大B细胞淋巴瘤患者tisagenlecleucel治疗的实际世界结果:一项全国性登记研究

2025-12-240
PRE
Case Report: Immunophenotypically diverse immature patterns; including variable TdT expression; in aggressive B-cell lymphomas and leukemia with MYC rearrangement

病例报告:免疫表型多样的幼稚细胞模式;包括TdT表达的可变性;在伴有MYC重排的侵袭性B细胞淋巴瘤和白血病中

2025-10-090
OAAI
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
2024-08-210
PRE
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

daratumumab后elotuzumab治疗多发性骨髓瘤的疗效恶化: 一项多中心回顾性研究

2024-03-161
PRE
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
2023-03-295
OAAI
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
2022-12-132
OAAI
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

卡非佐米-来那度胺-地塞米松和卡非佐米-地塞米松在复发/难治性多发性骨髓瘤中的真实世界有效性和安全性分析: 多中心回顾性分析

2022-06-248
OAAI
Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma

骨髓活检和流式细胞术分析的结合: 弥漫性大b细胞淋巴瘤中检测骨髓浸润的预后相关的中心方法

2021-09-206
OAAI
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
2021-03-281
PRE
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma

硼替佐米,美法仑和泼尼松龙四个周期的序贯疗法,然后连续来那度胺和地塞米松治疗不符合移植条件的新诊断多发性骨髓瘤

2019-11-255
PREAI